Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
株式のランク #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
株価
$0.01292666
最終同期: 2025-04-08
時価総額
$157.54K
変化(1日)
6.84%
変化(1年)
0.00%
GB
取引 Synairgen plc (SNG)

カテゴリー

Synairgen plc(SNG)の発行済株式数
June 2024 時点の発行済株式数 201.38M
Synairgen plc の最新の財務報告および株価によると、現在の発行済株式数は 201.38M です。December 2022 の終わりには、同社は 201.36M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Synairgen plc(SNG)の発行済株式数の履歴(2004 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 201.38M 0.00%
2023 201.38M 0.01%
2022 201.36M 0.46%
2021 200.44M 36.24%
2020 147.12M 33.64%
2019 110.09M 15.56%
2018 95.26M 1.15%
2017 94.18M 2.48%
2016 91.90M 0.64%
2015 91.32M 3.77%
2014 88.00M 16.35%
2013 75.64M 4.37%
2012 72.47M 19.66%
2011 60.56M 0.77%
2010 60.10M 154.94%
2009 23.57M 8.03%
2008 21.82M -9.98%
2007 24.24M 1.94%
2006 23.78M 26.20%
2005 18.84M 85.90%
2004 10.14M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 26.08%
US
62.19M -69.12%
NL
- -
CH
- -
KR
0.00 -100.00%
BE